Login to Your Account

Other News To Note

Thursday, March 24, 2011
strong>• Eisai Co. Ltd., of London, received European approval for Halaven (eribulin), a nontaxane, microtubule dynamics inhibitor, in patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription